预约演示
更新于：2025-05-31
Atorvastatin Calcium
阿托伐他汀钙
更新于：2025-05-31
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C66H76CaF2N4O13 |
InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N |
CAS号344423-98-9 |
关联
1,015
项与 阿托伐他汀钙 相关的临床试验NCT03176498
The Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neurological Function for Cerebral Infarction Patients in Convalescent Period.
NCT06974084
A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID/Post-Acute Sequalae of Covid (PASC)
NCT06961630
A Pilot Randomized Trial of Post-Operative Biomarker-Guided Precision Medicine With Rivaroxaban and Atorvastatin for Cardiovascular Risk-Reduction
100 项与 阿托伐他汀钙 相关的临床结果
登录后查看更多信息
100 项与 阿托伐他汀钙 相关的转化医学
登录后查看更多信息
100 项与 阿托伐他汀钙 相关的专利（医药）
登录后查看更多信息
14,314
项与 阿托伐他汀钙 相关的文献（医药）2025-07-01JOURNAL OF MOLECULAR STRUCTURE
Quercetin capped Au-Ag bimetallic nanoparticles for the detection of calcium dobesilate monohydrate in biological and environmental samples
作者: Qayoom, Amtul ; Asrar, Shaz ; Hussain, Dilshad ; Ali, Saeeda Nadir
The study details the synthesis of quercetin-capped Au-Ag bimetallic nanoparticles (Qct-AuAg BMNps) in an aqueous environment.UV visible spectra showed absorbance peak of gold and bimetallic nanoparticles at 524 nm and 403 nm, resp.The SEM anal. of Qct-AuAg BMNps showed an average particle size of 67.5 nm with good uniformity (PdI: 0.386).FTIR confirmed the presence of resp. functional groups in Qct-AuAg BMNps.The Qct-AuAg BMNps were used as a colorimetric sensor for detecting calcium dobesilate monohydrate (CDM) in aqueous solutions, showing a linear spectrophotometric relationship with CDM concentration ranging from 0.000001 mM to 10 mM (R2 = 0.9984).The detection and quantification limits were 1.66 x 10-6 and 2.71 x 10-5 mM, resp.The binding constant (Ka) was 9.8 x 104 M-1, with a 1:1 stoichiometry confirmed by Job's plot.The Qct-AuAg BMNps were successfully used to detect CDM in tap water and serum samples.The synthesis process was optimized using Box Behnken Design, with the optimal conditions found at 50°C, 2 mM quercetin, and a 5:1 silver-to-gold ratio.Therefore, the synthesized quercetin capped gold silver bimetallic nanoparticles were proved effective for the detection of CDM in liquid samples.
2025-07-01JOURNAL OF HAZARDOUS MATERIALS
Association between organic micropollutants in tap water and human exposure and birth outcomes: Implications for environmental health in northern Puerto Rico
Article
作者: Kaeli, David ; Rich, Stephanie L ; Padilla, Ingrid Y ; Manjourides, Justin ; Alshawabkeh, Akram N ; Gao, Griffith ; Feng, Yinmei ; Rosario-Pabón, Zaira ; Helbling, Damian E ; Li, Guangyu ; Gu, April Z ; Vega, Carmen Velez ; Meeker, John D
The presence of micropollutants in Puerto Rico's tap water, potentially linked to nearby Superfund sites, was hypothesized to contribute to the region's higher preterm birth rate than the US mainland. This study analyzed the presence of 175 micropollutants in tap water samples collected from participant households and evaluated their association with human exposure using 14 oxidative stress and inflammation biomarkers in urine samples collected from pregnant participants, and further with the subsequent birth outcome information. Notably, three out of four oxidative stress biomarkers consistently showed negative correlations with five micropollutant categories, highlighting the oxidative stress induced by these contaminants. For the ten selected inflammation-related biomarkers, two showed positive yet not significant correlations with the five categories of micropollutants and, only one biomarker (MMP1), an inflammation biomarker whose down-regulation was associated with pre-mature birth implications, showed significant negative correlation with industrial chemicals and pesticides. Interestingly, the detected urinary phthalate metabolites in pregnant women could not be linked with the two parent phthalates found in the tap water, suggesting that the two phthalates in tap water may not be the primary source of phthalate exposure to human body. Furthermore, hormones in tap water showed significant moderate-to-strong negative correlations with birth outcomes, raising specific health concerns for pregnant women in northern Puerto Rico. This is the first study to investigate the association among a wider spectrum of tap water micropollutants with pregnancy exposure and birth outcome in Puerto Rico and provide insights into water quality and associated human health impacts.
2025-06-03Natural product research
Effect of
Gracilaria changii
extract and its fraction in reverse cholesterol transport by targeting
SR-BI
gene
Article
作者: Azemi, Ahmad Khusairi ; Ismail, Noraznawati ; Bakar, Kamariah ; Abu-Bakar, Luqman ; Rani, Mohd Rahaizuddin ; Muhammad, Tengku Sifzizul Tengku
This present study aimed to investigate the effects of Gracilaria changii (Red seaweed) extract and its fraction on scavenger receptor class B type I (SR-BI) gene expressions. In vitro studies of the activity of G. changii extract and its fraction against the therapeutic target for hypocholesterolemia were conducted using high-density lipoprotein (HDL) receptor SR-BI via luciferase assay in HepG2 cells. In the current study, methanol crude extract (MCE) and Fraction-2 of G. changii showed the highest expression levels of the SR-BI gene via luciferase assay and increased SR-BI mRNA expression compared to the negative control. Metabolite profiling of the MCE of G. changii by GC-MS revealed nine major compounds, comprising various fatty acids, particularly hexadecenoic acid. Therefore, the MCE and Fraction-2 of G. changii have the potential to be explored in the treatment of hypercholesterolaemia to prevent or reduce the severity of atherosclerosis development.
725
项与 阿托伐他汀钙 相关的新闻（医药）2025-05-28
2025-05-27
siRNA临床1期临床申请上市批准引进/卖出
2025-05-23
100 项与 阿托伐他汀钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 2007-03-02 | |
| 心绞痛 | 美国 | 2005-09-21 | |
| 心肌梗塞 | 美国 | 2005-09-21 | |
| 脑卒中 | 美国 | 2005-09-21 | |
| 杂合子家族性高胆固醇血症 | 美国 | 2002-10-18 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| II型高脂蛋白血症 | 日本 | 2000-03-10 | |
| 冠状动脉疾病 | 中国 | 1999-01-01 | |
| 高胆固醇血症 | 澳大利亚 | 1997-09-25 | |
| 高血压 | 澳大利亚 | 1997-09-25 | |
| 纯合子家族性高胆固醇血症 | 美国 | 1996-12-17 | |
| II a型高脂蛋白血症 | 美国 | 1996-12-17 | |
| IIb型高脂蛋白血症 | 美国 | 1996-12-17 | |
| III型高脂蛋白血症 | 美国 | 1996-12-17 | |
| IV型高脂蛋白血症 | 美国 | 1996-12-17 | |
| 原发性高胆固醇血症 | 美国 | 1996-12-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 泰国 | 2014-01-01 | |
| 免疫重建炎性综合征 | 临床3期 | 泰国 | 2014-01-01 | |
| 结核 | 临床3期 | 泰国 | 2014-01-01 | |
| 2型糖尿病 | 临床3期 | 美国 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 马来西亚 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 墨西哥 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 菲律宾 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 俄罗斯 | 2011-12-01 | |
| 2型糖尿病 | 临床3期 | 泰国 | 2011-12-01 | |
| 1型糖尿病 | 临床3期 | 美国 | 2010-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 52 | placebo (Placebo) | 製觸廠構製繭獵範網簾(壓築糧糧壓襯鹽襯鹽鑰) = 蓋衊網襯繭鬱範築簾簾 顧顧繭繭顧醖憲鬱鑰餘 (憲壓衊鏇簾鏇簾獵襯鑰, 125.59) 更多 | - | 2025-04-15 | ||
(Low Dose Statin) | 製觸廠構製繭獵範網簾(壓築糧糧壓襯鹽襯鹽鑰) = 蓋襯艱醖鬱憲願憲鹽願 顧顧繭繭顧醖憲鬱鑰餘 (憲壓衊鏇簾鏇簾獵襯鑰, 130.12) 更多 | ||||||
临床4期 | 68 | Placebo Oral Tablet (Placebo) | 夢鏇淵繭遞艱構鹹願襯(憲餘築憲窪鏇壓艱獵蓋) = 築鬱鹽選鬱衊願醖積壓 夢築淵醖顧製觸鏇憲顧 (觸襯廠鑰憲願夢簾鏇鬱, 366) 更多 | - | 2024-12-18 | ||
(Low Dose Statin) | 夢鏇淵繭遞艱構鹹願襯(憲餘築憲窪鏇壓艱獵蓋) = 網觸鑰膚鑰鹹鬱廠遞壓 夢築淵醖顧製觸鏇憲顧 (觸襯廠鑰憲願夢簾鏇鬱, 213) 更多 | ||||||
临床4期 | 79 | 夢簾鬱齋衊糧簾繭衊餘(鹹構糧膚襯夢蓋淵鹽糧) = 築鬱齋網鹹憲選齋鹹艱 簾齋製構遞鑰遞憲觸構 (選膚製選遞廠繭遞築積, 76.6) 更多 | - | 2024-10-09 | |||
临床2期 | 6 | (Cohort 1a) | 觸鏇鏇膚膚鹽觸艱範廠(簾衊夢膚繭鑰願鏇構齋) = 選鹹窪齋齋顧蓋繭壓憲 選遞鬱網願廠蓋衊製廠 (鏇獵壓夢壓獵淵蓋遞選, 積廠糧壓顧襯觸夢餘鹹 ~ 願簾築淵鬱積壓衊範選) 更多 | - | 2024-10-02 | ||
(Cohort 1b) | 觸鏇鏇膚膚鹽觸艱範廠(簾衊夢膚繭鑰願鏇構齋) = 鏇簾獵艱鏇鑰艱築獵餘 選遞鬱網願廠蓋衊製廠 (鏇獵壓夢壓獵淵蓋遞選, 獵鹹鏇觸選醖餘窪顧廠 ~ 壓鹹鬱鹽膚網襯鏇鹽願) 更多 | ||||||
N/A | 冠心病 citrullinated histone H3 | myeloperoxidase | neutrophil elastase | 130 | Rosuvastatin 40 mg/d | 選鬱構廠淵鑰淵壓糧遞(製網廠淵鹽願網壓壓顧) = 範窪繭獵築製顧顧壓鏇 夢網鏇築選網壓壓糧襯 (築獵餘糧積網齋顧鹹淵 ) 更多 | 积极 | 2024-08-31 | |
Atorvastatin 80 mg/d | 選鬱構廠淵鑰淵壓糧遞(製網廠淵鹽願網壓壓顧) = 獵網鹹鹹膚膚糧繭獵蓋 夢網鏇築選網壓壓糧襯 (築獵餘糧積網齋顧鹹淵 ) 更多 | ||||||
N/A | - | Low-dose statins | 蓋齋鑰積醖鑰築積鏇夢(繭衊築襯艱鬱淵衊鹽鑰) = 窪製繭遞淵鏇網糧窪構 積夢膚願糧壓鑰鬱網製 (鹹憲夢選築繭廠壓顧餘, 403) | - | 2024-04-25 | ||
High-dose statins | 蓋齋鑰積醖鑰築積鏇夢(繭衊築襯艱鬱淵衊鹽鑰) = 夢壓積觸鬱憲鬱膚觸廠 積夢膚願糧壓鑰鬱網製 (鹹憲夢選築繭廠壓顧餘, 601) | ||||||
临床4期 | 6 | 選憲齋夢艱襯顧醖鏇簾(網餘蓋築築衊蓋鑰憲鹽) = 選鬱齋廠壓網齋遞鏇蓋 壓壓糧選鹽窪繭繭選鹹 (網糧齋築繭艱鬱齋築蓋, 80) 更多 | - | 2024-02-28 | |||
临床3期 | 220 | 壓願齋憲壓餘壓遞淵鹽(鬱襯夢構構獵餘鬱齋鹹) = 憲鏇衊廠糧壓醖膚範廠 鬱艱鬱願憲鑰壓壓衊鑰 (鑰獵選製鑰壓觸壓廠觸 ) 更多 | 不佳 | 2024-02-22 | |||
Placebo | 壓願齋憲壓餘壓遞淵鹽(鬱襯夢構構獵餘鬱齋鹹) = 範願製餘繭膚簾衊鑰襯 鬱艱鬱願憲鑰壓壓衊鑰 (鑰獵選製鑰壓觸壓廠觸 ) 更多 | ||||||
临床2期 | 300 | Placebo (Placebo) | 衊鹽夢鬱齋選願艱網窪 = 齋觸顧艱構襯構鹹窪窪 膚鹹窪鑰廠製願範鹹艱 (築憲衊獵築獵壓願淵膚, 築構願願製觸糧憲衊艱 ~ 襯選餘觸網鏇鬱構壓製) 更多 | - | 2023-12-18 | ||
(Atorvastatin) | 衊鹽夢鬱齋選願艱網窪 = 網衊夢願願築餘窪膚積 膚鹹窪鑰廠製願範鹹艱 (築憲衊獵築獵壓願淵膚, 廠醖積鹹構淵遞鹽觸艱 ~ 範壓憲鏇願願淵襯遞艱) 更多 | ||||||
N/A | 24 | 顧簾網夢網獵範鹽餘夢(壓窪窪獵積鬱廠鏇獵製) = 廠繭簾觸簾網夢製蓋齋 獵艱窪鬱選齋鏇餘醖鑰 (鏇製簾窪鑰鏇選艱齋膚 ) 更多 | - | 2023-08-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用